Table 1.

Relationship of BRAF V600E and TERT C228T Mutations With Clinicopathologic Outcomes of PTC

PTC Type and Clinicopathologic Outcomes	BRAF Status							TERT Status
	BRAF V600E			Wild-Type BRAF			P	TERT C228T			Wild-Type TERT			P
	No.	%	No. of Missing Cases	No.	%	No. of Missing Cases		No.	%	No. of Missing Cases	No.	%	No. of Missing Cases
All PTC
Total No. of cases	194			313				61			446
Age at diagnosis, years*	47.1 ± 14.4			45.2 ± 13.8			.138	51.7 ± 15.7			45.1 ± 13.6			< .001
Sex, male	69	35.6		73	23.3		.003	32	52.5		110	24.7		< .001
Tumor size, cm			12			9	.003			6			15	.048
Median	2.0			1.7				2.3			1.8
Interquartile range	1.3-3.0			1.0-2.8				1.2-3.5			1.1-3.0
Multifocality	68	36.4	7	122	39.1	1	.542	20	33.9	2	170	38.6	6	.482
Extrathyroidal invasion	58	31.3	9	35	11.2	1	< .001	27	46.5	3	66	15.0	7	< .001
Vascular invasion	36	20.0	14	41	13.2	2	.045	14	25.9	7	63	14.4	9	.028
Lymph node metastasis	85	46.2	10	68	21.7		< .001	31	52.5	2	122	27.8	8	< .001
Distant metastatic recurrence	12	6.2		10	3.2		.108	12	19.7		10	2.2		< .001
Disease stage			6										6
I	114	60.6		237	75.7			26	42.6		325	73.9
II	13	6.9		31	9.9			6	9.8		38	8.6
III	39	20.7		35	11.2			12	19.7		62	14.1
IV	22	11.7		10	3.2		< .001	17	27.9		15	3.4		< .001
III + IV	61	32.4		45	14.4		< .001	29	47.5		77	17.5		< .001
Tumor recurrence	50	25.8		30	9.6		< .001	29	47.5		51	11.4		< .001
Total 131I dose, mCi			16			7	.004			7			16	.001
Median	87.7			74.9				100			75
Interquartile range	0-100			0-100				29.9-105			0-100
Total follow-up, months							.027							.056
Median	18			31				30			24
Interquartile range	7-53			8-87				12-78			6-76
CPTC
Total No. of cases	164			219				47			336
Age at diagnosis, years*	46.7 ± 13.7			45.8 ± 13.9			.511	51.6 ± 16.0			45.4 ± 13.4			.004
Sex, male	60	36.6		53	24.2		.009	25	53.2		88	26.2		< .001
Tumor size, cm			12			9	< .001			6			15	.009
Median	2			1.5				2.3			1.6
Interquartile range	1.3-3			0.8-2.3				1.2-3.5			1-2.5
Multifocality	54	34.4	7	87	39.9	1	.277	16	35.6	2	125	37.9	6	.763
Extrathyroidal invasion	48	31.0	9	29	13.3	1	< .001	23	52.3	3	54	16.4	7	< .001
Vascular invasion	27	18.0	14	27	14.4	2	.140	10	25.0	7	44	13.5	9	.052
Lymph node metastasis	76	49.0	9	58	26.5		< .001	27	60.0	2	107	32.5	7	< .001
Distant metastatic recurrence	7	4.3		8	3.6		.759	8	17.0		7	2.1		< .001
Disease stage			6										6
I	98	62.0		172	78.5			19	40.3		251	76.1
II	10	6.3		15	6.9			3	6.4		22	6.7
III	32	20.2		23	10.5			10	21.3		45	13.6
IV	18	11.4		9	4.1		.001	15	31.9		12	3.6		< .001
III + IV	50	31.6		32	14.6		< .001	25	53.2		57	17.3		< .001
Tumor recurrence	42	25.6		22	10.0		< .001	24	51.1		40	11.9		< .001
Total 131I dose, mCi			15			5	.043			7				< .001
Median	75			51.7				100			75
Interquartile range	0-100			0-100				75-104			0-100
Total follow-up, months							.026							.026
Median	19			32				48			24
Interquartile range	6.5-52			9-80				12-95			6-70

Abbreviations: CPTC, conventional papillary thyroid cancer; PTC, papillary thyroid cancer.

^*Data were summarized with means ± standard deviations.